Production (Stage)
ADMA Biologics, Inc.
ADMA
$20.42
$0.261.29%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 114.80M | 117.55M | 119.84M | 107.19M | 81.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 114.80M | 117.55M | 119.84M | 107.19M | 81.88M |
| Cost of Revenue | 53.71M | 54.22M | 60.18M | 49.74M | 42.77M |
| Gross Profit | 61.10M | 63.33M | 59.66M | 57.45M | 39.11M |
| SG&A Expenses | 25.37M | 24.59M | 19.58M | 17.55M | 16.64M |
| Depreciation & Amortization | 25.00K | 25.00K | 28.00K | 142.00K | 193.00K |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 79.92M | 79.23M | 80.20M | 67.99M | 60.05M |
| Operating Income | 34.88M | 38.32M | 39.64M | 39.20M | 21.82M |
| Income Before Tax | 33.45M | 34.71M | 36.75M | 35.85M | 18.40M |
| Income Tax Expenses | 6.55M | -77.18M | 840.00K | 3.79M | 595.00K |
| Earnings from Continuing Operations | 26.90M | 111.90M | 35.91M | 32.06M | 17.81M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 26.90M | 111.90M | 35.91M | 32.06M | 17.81M |
| EBIT | 34.88M | 38.32M | 39.64M | 39.20M | 21.82M |
| EBITDA | 36.85M | 40.27M | 41.58M | 41.25M | 23.94M |
| EPS Basic | 0.11 | 0.47 | 0.15 | 0.14 | 0.08 |
| Normalized Basic EPS | 0.09 | 0.10 | 0.10 | 0.10 | 0.05 |
| EPS Diluted | 0.11 | 0.46 | 0.15 | 0.13 | 0.08 |
| Normalized Diluted EPS | 0.09 | 0.09 | 0.09 | 0.09 | 0.05 |
| Average Basic Shares Outstanding | 237.78M | 236.43M | 234.57M | 232.42M | 228.87M |
| Average Diluted Shares Outstanding | 244.68M | 245.90M | 244.80M | 242.17M | 236.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |